Documents to download

Growth promoting hormones have been at the centre of a long running trade dispute between the EU and US. The problem arises because of an EU ban on imports of meat from cattle treated with such hormones. Beef producers in the US, Canada and elsewhere commonly treat their cattle with hormone growth promoters; EU policy thus prevents such beef being sold on the European market. While the EU maintains that the policy is based on scientific evidence regarding possible health concerns, the US complained to the World Trade Organisation (WTO) that the EU ban was no more than a trade barrier disguised as health measures. In February 1998, a WTO Dispute Settlement Body ruled that the EU ban violated international trade rules. The EU now has until 13 May 1999 to comply with its WTO obligations. This POSTnote looks at the scientific basis of the EU policy and examines the options open to the EU in the light of the WTO ruling.


Documents to download

Related posts

  • There are various applications of Artificial Intelligence (AI) in healthcare, such as helping clinicians to make decisions, monitoring patient health, and automating routine administrative tasks. This POSTnote gives an overview of these uses, and their potential impacts on the cost and quality of healthcare, and on the workforce. It summarises the challenges to wider adoption of AI in healthcare, including those relating to safety, privacy, data-sharing, trust, accountability and health inequalities. It also outlines some of the regulations relevant to AI, and how these may change. As healthcare is a devolved issue, policies on healthcare AI differ across the UK. This POSTnote focusses on regulations and policies relevant to England.

  • The rapid production of safe, effective and consistent vaccines is essential for supporting COVID-19 immunisation programmes in the UK and globally. However, manufacturing vaccines is challenging for various reasons that include the complex processes involved, the specialist knowledge and experience required, and the natural variability of the biological materials and systems used. Urgent demand is leading to manufacturers and governments taking on significant financial risks in order to speed up production. What is the UK Government doing to accelerate vaccine manufacture? How are vaccines made? Why is manufacturing vaccines at large scales so challenging?